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Carcinoma cells can lose their epithelial cell characteristics and dedifferentiate into a fibroblast-like cell during progression of a
neoplasm. Aberrant expression of oligomeric transcriptional complexes contributes to progression of carcinomas. Although individual
transcription factors initiating progression remain unknown, LIM-only protein (LMO) and LIM-domain binding protein (LDB)
negatively regulate breast carcinoma cell differentiation. In this study, we investigated the expression of LMO4 and LDB in squamous
cell carcinomas of the oral cavity. LMO4 mRNA was amplified in four of six carcinoma tissues and eight of 12 carcinoma cell lines, and
LDB1 in three carcinoma tissues and 11 cell lines examined. Immunoprecipitation studies revealed that LMO4 and LDB1 interact with
each other in the nuclear milieu of the carcinoma cells indicating the presence of an LMO4-LDB1-mediated transcription complex.
Both LMO4 and LDB1 proteins were preferentially localised in the nuclei of carcinoma cells at the invasive front and the
immunoreactivity was increased in less-differentiated carcinoma tissues (Po0.01). Carcinoma cells metastasised to the cervical lymph
nodes with increased immunoreactivity compared to the primary site of neoplasm (Po0.05). These data suggest that the LMO4–
LDB1 complexes may be involved in carcinoma progression possibly through dedifferentiation of squamous carcinoma cells of the
oral cavity.
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Oral squamous cell carcinoma is the most common neoplasm of
the head and neck. Worldwide, the annual incidence of new cases
exceeds 300000. The disease causes great morbidity, and the 5-year
survival rate has not improved in more than two decades (Vokes
et al, 1993; Lippman and Hong, 2001). With few exceptions,
carcinomas are derived from single somatic cells and their
progeny. Carcinoma cells in the emerging neoplastic clone
accumulate within them a series of genetic and/or epigenetic
changes that lead to changes in gene activity, and altered
phenotypes which are subjected to selection of tumour progression
(Ponder, 2001). The generation of cellular diversity in carcinomas
frequently involves aberrant expression of transcriptional regula-
tors acting in a combinational manner. Loss of epithelial
morphology and acquisition of mesenchymal characteristics, often
referred to as the epithelial–mesenchymal transition, are typical
for carcinoma cells in dedifferentiation and correlate with tumour
progression (Hay, 1995; Birchmeire et al, 1996; Thiery, 2002).
However, the genetic basis of dedifferentiation and progression of
carcinoma cells has not been determined.
The LIM-only (LMO) protein carries two tandemly repeat LIM
zinc-binding domains and consists of four members (designated as
LMO1–4). The LIM domain has been identified in a variety of
nuclear proteins (Sanchez-Garcia and Rabbitts, 1994). It functions
primarily as a module for the assembly of protein complexes
through protein–protein interactions. The LIM domain does not
directly interact with DNA, but acts as an adaptor molecule for
transcription factors facilitating assembly of large transcriptional
complexes (Breen et al, 1998; Jurata et al, 1998; Sugihara et al,
1998). LMO1 and LMO2 have been shown to specify neuronal and
haematopoietic cell lineages in combination with their transcrip-
tion partners (Hinks et al, 1997; Yamada et al, 1998; Herblot et al,
2000). Misexpression of these genes by chromosomal translocation
abrogates proper differentiation of cells and is oncogenic within T
cells (Boehm et al, 1991; Royer-Pokora et al, 1991). Little is known
about LMO3, which was discovered on the basis of sequence
homology. The most recently identified member, LMO4, shares
only 50% homology with the LIM domains of other LMO proteins.
The LMO4 gene is widely distributed in embryonic tissues (Kenny
et al, 1998; Sugihara et al, 1998), and involved in negative
regulation of breast carcinoma cell differentiation (Visvader et al,
2001). LMO4 binds with a high affinity to the LIM domain-binding
proteins, LDB1 (CLIM2, NLI1) and LDB2 (CLIM1) (Agulnick et al,
1996; Jurata et al, 1996; Sugihara et al, 1998). LDB proteins bind to
transcription factors directly or indirectly mediated through LMO
proteins, and then bridge a unique bipartite DNA sequence
separated by about one helix turn from each other (Agulnick et al,
1996; Jurata et al, 1996; Wadman et al, 1997; Rabbitts, 1998). Both
LMOs and LDBs are widely expressed during development (Kenny
et al, 1998; Millan et al, 1998; Toyama et al, 1998; Hermanson et al,
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and lineage determination, and oncogenesis (Jurata et al, 1998;
Mila ´n et al, 1998; Rabbitts, 1998; Thaler et al, 2002).
Prompted by the observation that LMO4 and LDB1 are
expressed in embryonic epithelial tissues (Bach et al, 1997;
Sugihara et al, 1998), we examined the expression pattern
of LMO4 and LDBs in squamous carcinoma cells. In contrast to
the negligible expression of LDB2, LMO4 and LDB1 were
frequently detected in the less-differentiated carcinomas and
carcinoma cells at the invasive front, and upregulated in
metastasised lymph nodes, suggesting an involvement of the
LMO4–LDB1 transcriptional complex in the pathology of carci-
noma progression.
MATERIALS AND METHODS
Cell lines and tissue samples
Immortalised cell lines established from oral squamous carcino-
mas (Ca9.22, Ho1N1, HOC313, HSC2, HSC3, HSC4, KOSC2,
KOSC3, OSC19, SCCKN, SCCTF, and TSU) were obtained
from the Cell Resource Center for Biomedical Research Institute
of Development, Aging and Cancer (Tohoku University,
Sendai, Japan), Health Science Research Resources Bank
(Osaka, Japan) or RIKEN Cell Bank (Tsukuba, Japan), and
maintained in 10% fetal bovine serum (FBS)-containing DMEM
or RPMI1640 medium (Invitrogen, Grand Island, NY, USA) in a
5% CO2 incubator. Normal gingival fibroblasts (GF12) were
maintained in 10% FBS containing DMEM for 19 passages
(Takahashi et al, 1997). HaCaT cells (Boukamp et al, 1988),
immortalised normal keratinocytes, were grown in DMEM
supplemented with 10% FBS.
A total of six oral carcinoma tissues (three well-differentiated
carcinomas and three moderately differentiated carcinomas) and
three normal oral tissues without a history of head and neck
carcinoma were obtained from patients undergoing surgery for
carcinoma resection or dental surgery at the Nippon Dental
University Hospital, Meikai University Hospital, or Machida City
Hospital under the informed consent of the patients.
Reverse transcription–PCR
Total RNA was isolated from cell lines at 70–85% confluency, oral
squamous cell carcinomas, and normal oral tissues using TRIzol
reagent (Invitrogen) followed by RNase-free DNase I treatment to
eliminate DNA contamination in the sample. After reverse
transcription (RT) to a single-stranded cDNA using SuperScript
II (Invitrogen) and random hexamer (Invitrogen) at 421C for
60min, PCR reaction was performed with gene-specific primer sets
for LMO4 (forward: exon 4; 50-CGGGAGATCGGTTTCACTAC,
reverse: exon 5; 50-CCAGTGCCCTGCTAATTGTT), LDB1 (forward:
exon 5; 50-TGCCATGTTGACCATCACTT, reverse: exon 9; 50-GGC-
TGAGGCTGTAGGTCTTG), LDB2 (forward: exon 1; 50-TTTCGA-
AAAGCAGGCAAGAT, reverse: exon 6; 50-TCGGGGACTGAGGTT-
GTAAG), or GAPDH (forward: 50-GTCAGTGGTGGACCAGACCT,
reverse: 50-AGGGGAGATTCAGTGTGGTG) and Taq DNA poly-
merase (Invitrogen). PCR amplification was performed by running
30 cycles under the following conditions: denatured at 941C for
40s, annealed for 40s at 601C, and extended at 721C for 1min. PCR
amplicons were analysed on 2% agarose gels.
Tissue specimen selection
Incisional or excisional biopsy specimens from 49 patients with
oral squamous cell carcinomas were collected from the files of The
Kanazawa University Hospital from 1991 to 2000 under informed
consent of the patients. Clinical and pathological data were
obtained from the patients’ medical records and The Kanazawa
University Hospital Surgical Pathology files. Clinical and patho-
logic variables included age, gender, tumour size, tumour location,
grade of tumour differentiation, and presence or absence of
cervical lymph node metastasis. Control normal tissues (n¼5)
were also obtained at surgery or autopsy from tongue and gingiva
of patients without a history of head and neck cancer. These
samples were immediately fixed in 10% neutral buffered formalin
or periodate–lysine–paraformaldehyde (PLP) solution and em-
bedded in paraffin wax.
Immunohistochemistry
The haematoxylin and eosin-stained slides from each of the cases
were screened by light microscopy. Unstained serial sections
(4mm) were deparaffinised and rehydrated followed by the
microwave treatment in 0.01 M sodium citrate buffer, pH 6.0
(500W). After incubation with normal serum, sections were
incubated with rabbit anti-LMO4 (5mgml
 1, Chemicon, Temecula,
CA, USA), goat anti-LDB1 (2mgml
 1, Santa Cruz Biotechnology,
Santa Cruz, CA, USA) or goat anti-LDB2 (2mgml
 1, Santa
Cruz Biotechnology) antibodies for 12h at 41C. Biotinylated
anti-rabbit or -goat IgG (DAKO, Glostrup, Denmark) was used
for secondary antibody followed by incubation with avidin–biotin
complexes (Vector Laboratories, Burlingame, CA, USA). The
colour was developed with 3,30-diaminobenzidine tetrahydrochlor-
ide (Sigma-Aldrich, St Louis, MI, USA) under the microscope
and counterstained with methyl green. To clarify the specificity of
the antibody reactivity, primary antibodies were replaced
with either nonimmune rabbit or goat IgG (DAKO) at matched
protein concentrations. Carcinoma cells with a strong nuclear
labelling were determined as positive reactions, but cells with
a weak nuclear staining and/or diffuse cytoplasmic staining were
not counted as positive. The percentage of positive nuclear
staining of LMO4 or LDB1 was evaluated by counting at least
3000 carcinoma cells in randomly selected areas of each specimen
at  40. They were blinded as to the clinicopathological
parameters.
Immunocytochemistry
Human oral squamous carcinoma cell lines (TSU, HOC313, HSC3,
and OSC19) were cultured on glass slides (Lab-Tek Chamber II,
NUNC, Naperville, IL, USA) in 10% FBS-containing medium and
fixed in 1% paraformaldehyde for 3min at 231C. The cells were
reacted with primary antibodies to LMO4 (10mgml
 1), LDB1
(4mgml
 1), or LDB2 (4mgml
 1) for 16h at 41C. Alexa Fluor 546
anti-rabbit or -goat IgG (Molecular Probes, Eugene, OR, USA) was
used for secondary antibody. To clarify the specificity of antibody
reactivity, incubation with nonimmune rabbit IgG or goat IgG at
matched protein concentrations instead of primary antibodies was
performed.
Immunoprecipitation
For detection of endogenous protein binding, crude nuclear
extracts (30mg) of HSC3, TSU, OSC19, or HOC313 cells were
prepared by the method described elsewhere (Digman et al, 1983;
Lee et al, 1998), immunoprecipitated with goat anti-LDB1 antibody
(2mg) and protein G-Sepharose (Pharmacia, Wikstro ¨ms,
Sweden), and size fractionated by SDS–PAGE (10% total
acrylamide) under reducing condition. After electrotransfer to
nitrocellulose membranes, membranes were blocked by 3%
bovine serum albumin and incubated with rabbit anti-LMO4 or
goat anti-LDB1 antibodies, followed by incubation with biotiny-
lated secondary antibodies. Avidin–biotin complex and 3,30-
diaminobenzidin tetrahydrochloride were used for the colour
development.
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One-way analysis of variance followed by contrast statements
(Scheffe’s F-test and Fisher’s PLSD) was performed to compare
LMO4 or LDB1 immunoreactivity with carcinoma differentiation
and other clinical and pathological parameters recorded in the
text. Statistical analysis of correlation between the immunoreac-
tivity of LMO4 and LDB1 was conducted by simple linear
regression and between primary site and metastasised lymph
nodes by Wilcoxon’s signed-rank test.
RESULTS
Expression of LMO4, LDB1, and LDB2 in oral carcinomas
Expression of LMO4, LDB1, and LDB2 in squamous cell
carcinomas has not been investigated. We therefore examined
the expression pattern of these genes in carcinoma tissues of the
oral cavity by RT–PCR (Figure 1A). Based on the human genome
database (http://www.ncbi.nlm.nih.gov/blast/Blast.cgi), primer sets
for LMO4, LDB1,o rLDB2 were designed as spanning one or more
introns to prevent amplification of genomic DNA. LMO4 and LDB1
exhibited an almost identical pattern of expression. Specific primer
sets for each gene amplified a single product; four of six and three
of six carcinomas for LMO4 (485bp) and LDB1 (494bp),
respectively. Normal gingiva obtained from patients without a
history of head and neck cancer also expressed the genes in one of
the three samples. Four carcinomas and two normal samples
augmented a single 702bp fragment of the LDB2 transcript.
We analysed RNA samples isolated from tissues containing
epithelial and mesenchymal components. To remove mesenchymal
cell contamination from carcinoma cells, we examined the
expression of LMO4, LDB1, and LDB2 in 12 different squamous
carcinoma cell lines (Figure 1B). LMO4 was amplified in eight of 12
cell lines and LDB1 in 11 of 12 carcinoma cell lines. LMO4 was
amplified in GF12 normal fibroblasts and LDB1 in GF12 and
HaCaT cell lines. LDB2 was only detected in GF12, but not in any
of the cell lines of epithelial origin.
Protein expression of LMO4 and LDB1, and interaction
in carcinoma cells
Since LMO4 and LDB1 were expressed in oral carcinomas, we
examined the binding between LMO4 and LDB1 proteins by
immunoprecipitation. LMO4 was coimmunoprecipitated with an
anti-LDB1 antibody in OSC19 and HOC313 cells, which expressed
LMO4 and LDB1 genes (Figure 2). The molecular size of LDB1 has
not been determined, but is expected to be around Mr 42809 from
the deduced amino-acid sequence. LDB1 exhibits a single reactive
protein band at Mr 40000. TSU cells, which amplified LDB1, but
not LMO4 genes, were immunoprecipitated only by LDB1 protein.
As expected, LMO4- and LDB1-negative HSC3 cells did not react
with the antibodies.
Immunocytochemistry stained the nuclei of HOC313 and OSC19
cells for LMO4, OSC19, HOC313, and TSU for LDB1, and none for
LDB2 (Figure 3A and C). HSC3 cells were not stained by antibodies
against LMO4 or LDB1 (Figure 3B and D). No staining was
observed with nonimmune IgG (data not shown). Specificity of the
antibodies used in this study was ascertained by nuclear
immunostainings and by the appropriate size of a single-reactive
band to the predicted molecular weight. Thus, these data
Normal Carcinomas
LMO4
LDB1
LDB2
GAPDH
LMO4
LDB1
LDB2
GAPDH
1234567 89
123456789 1 0 1 1 1 2 1 3 1 4
Carcinoma cell lines
GF12
HaCaT
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B
Figure 1 Expression of LMO4 and LDBs mRNA in oral squamous cell
carcinomas. (A) LMO4, LDB1, and LDB2 transcripts are amplified in normal
gingiva (lanes 1–3) and carcinoma tissues (lanes 4–9) by RT-PCR. A single
485, 494, or 702bp fragment was observed by a specific primer set for
LMO4, LDB1,o rLDB2, respectively. GAPDH (395bp) was included as an
internal control. (B) Oral squamous carcinoma cell lines were subjected to
RT–PCR analysis (lane 3; HOC313, lane 4; TSU, lane 5; HSC3, lane 6;
HSC4, lane 7; KOSC2, lane 8; Ho1N1, lane 9; Ca9.22, lane 10; SCCKN,
lane 11; KOSC3, lane 12; SCCTF, lane 13; HSC2, lane 14; OSC19). RNA
sample isolated from GF12 normal gingival fibroblasts (lane 1) and HaCaT
cells (lane 2) were applied as controls.
1234 1234 kDa
49
36
25
19
LMO4 LDB1
Figure 2 Analysis of protein interaction in squamous carcinoma cell lines.
Nuclear extracts from HSC3 (lane 1), TSU (lane 2), OSC19 (lane 3), or
HOC313 cells (lane 4) were immunoprecipitated using anti-LDB1
antibody. After SDS–PAGE, immunoblotting was performed using
antibodies specific to LMO4 or LDB1.
Figure 3 Immunocytochemisty of LMO4 or LDB1 in carcinoma cells.
Squamous carcinoma cells cultured on the slide glasses were applied for
immunostaining to LMO4 (A, B) or LDB1 (C, D). (A, C) HOC313 cells
(B, D) HSC3 cells. Bar¼50mm.
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in oral squamous carcinoma cells.
Tissue localisation of LMO4 and LDB1 in oral
carcinoma tissues
Clinical and pathological characteristics of the 49 patients with oral
squamous cell carcinoma were collected and analysed. The
samples were obtained from the tongue (20 cases), gingiva (15
cases), oral floor (six cases), buccal mucosa (five cases), lip (two
cases), or maxillal sinus (one case). The patients (21 males and 28
females) ranged from 37 to 92 years of age (mean, 66 years old).
Histopathological typing of carcinomas was classified into three
groups; well (21 cases), moderately (23 cases), and poorly (five
cases) differentiated carcinoma groups. None of the cases
represented were classified as squamous carcinomas with a
spindle-cell morphology. Lymph node tissues with metastasis of
carcinomas were also subjected to the immunohistochemistry
procedure (n¼7).
We localised LMO4 and LDBs in tissue sections by immuno-
staining using specific antibodies. Nuclear staining of LMO4 and
LDB1 was observed in 30 (61%) and 37 (76%) of 49 carcinomas,
respectively. Although minimal reaction of LDB2 immunostaining
was noted in inflammatory cells that infiltrated into the carcinoma
tissues, carcinoma cells did not react (data not shown). Normal
epithelium from gingiva or tongue did not stain with each
antibody, while an occasional reaction was observed in lympho-
cytes that infiltrated into the submucosal layer (Figure 4C). LMO4-
and/or LDB1-immunoreactive carcinoma cells were usually found
at the periphery of the carcinoma cell nests. In addition, the
reaction became more prominent in carcinoma cells at the invasive
front (Figure 4A and B). Fibroblast-like cells and infiltrating
lymphocytes surrounding carcinoma cells at the invasive front also
exhibited nuclear staining. To quantify the immunoreactivity, we
calculated the percentage of nuclear staining in carcinoma cells
and compared this to the clinicopathological parameters of the
samples. Immunoreactive carcinoma cells were observed in
18.69722.89% (mean71 s.d.) of LMO4 staining and
23.41722.44 of LDB1 staining. However, the percentage of
immunoreactive carcinoma cells was significantly increased in
less-differentiated carcinoma tissues (Po0.01) (Table 1) and their
immunoreactivity of LMO4 and LDB1 showed a positive
linear correlation (Figure 5A). We also compared the immuno-
reactivity between carcinoma cells at the primary site and
metastasised lymph nodes. Carcinoma cells in the lymph nodes
significantly increased the immunoreactivity of LMO4
(37.67722.60) and LDB1 (38.07723.84) compared to the corre-
sponding primary sites (LMO4; 13.46718.29, LDB1; 17.63714.99)
(Figure 5B). There was no statistical difference in the immunor-
eactivity with patient age, gender, and tumour size and grade
(data not shown).
DISCUSSION
Metastasis of squamous carcinoma cells to distant organs or lymph
nodes requires several steps, including detachment from the
primary site, dedifferentiation, invasion of the surrounding stroma
and vessel walls, embolism, and stromal invasion and prolifera-
tion. Dedifferentiation of carcinoma cells initiates carcinoma
progression toward a metastatic neoplasm (Vokes et al, 1993;
Birchmeire et al, 1996; Lippman and Hong, 2001). Investigation of
the molecular mechanism of carcinoma cell differentiation/
dedifferentiation is a momentous subject in cancer cell biology
and may contribute to the development of a novel strategy to
relieve patient suffering from the disease. Although investigators
reported that various factors are involved in carcinoma cell
differentiation and dedifferentiation, accumulating evidence im-
plies that transcriptional misregulation takes a critical part in the
events (Angel et al, 1996; Hunter, 1997; Visvader et al, 1997; Battle
et al, 2000; Cano et al, 2000). In the present study, our data
demonstrate for the first time that LMO4 and LDB1 form protein
complexes in the nucleus and are expressed in carcinoma cells at
the invasive front, and their immunoreactivity is increased in less-
differentiated carcinomas and in metastasised lymph nodes.
LMO4 and LDB1 are ubiquitously expressed in the mouse
embryos, including epithelial and mesenchymal areas, when
compared to the exclusive expression of other LMO family
members and LDB2 in neuronal and haematopoietic cells
(Visvader et al, 1997; Kenny et al, 1998; Sugihara et al, 1998;
Toyama et al, 1998; Hermanson et al, 1999; Thaler et al, 2002). The
LIM domain of LDBs contributes to the binding of transcription
factors, including LIM-homeodomain, zinc-finger and basic helix–
loop–helix (bHLH) proteins (Agulnick et al, 1996; Jurata et al,
1996; Bach et al, 1997; Morcillo et al, 1997). Formation of protein
complexes synergistically activates the expression of target genes
(Jurata et al, 1998; Mila ´n et al, 1998). In the presence of LMO
protein, it mediates the transcription factor binding to the LDB
protein or competes with the direct binding between LDB and the
transcription factor (Rabbitts, 1998; Thaler et al, 2002). These
combinational actions are involved in the diversity of transcrip-
tional regulation and specification of cell types (Visvader et al,
1997; Thaler et al, 2002). Misexpression of LMO1 and LMO2 by the
chromosomal translocation is observed in T-cell leukaemia and
Figure 4 Immunolocalisation of LMO4, LDB1, or LDB2 in carcinoma or
normal tissues. LMO4 (A) and LDB1 (B) were localised to carcinoma cells
and stromal cells at the invasive front. Lymphocytes infiltrated into the
submucosal layer of normal gingival were immunoreactive to LDB2 staining
(C). Broken line depicted the borderline between epithelium and
mesenchyme. Negative control staining with nonimmune goat IgG was
performed instead of primary antibody (D). Bar¼250mm (A, B, and D)
and 125mm (C).
Table 1 Association between LMO4 or LDB1 immunoreactivity and
histological tumour differentiation
Differentiation (n) LMO4 LDB1
Well 3.92 ± 7.72 11.11 ± 11.93
Moderate 24.29 ± 20.76   *  * 27.39 ± 21.12   *  *
Poor 54.92 ± 25.58   * 56.72 ± 24.58   *
(21)
(23)
(5)
Percentage of immunoreactive carcinoma cells were counted and compared to
histological differentiation grade by one-way analysis of variance and contrast
statements (mean71s.d.). *Po0.01.
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et al, 1998; Rabbitts, 1998). Although the role in the pathology of
carcinomas of epithelial origin is not clear, Visvader et al (2001)
recently indicated that LMO4 and LDB1 are required to maintain
the undifferentiation state of invasive breast carcinoma cells, and
the forced expression of LMO4 inhibits differentiation of
mammary epithelial cells. Increased expression of LMO4 and
LDB1 in less-differentiated oral carcinomas represented in this
study suggests an involvement in cellular dedifferentiation.
Carcinoma cells located at the invasive front also exhibited an
increase in immunoreactivity. Carcinoma cells located at the
invasive front enhance the characteristics of epithelial–mesen-
chymal transition, which initiates invasion into the collagen
matrices (Gobbert et al, 1985; Behrens et al, 1989; Frixen et al,
1991; Imai et al, 1995). Although the molecular mechanism of
LMO4–LDB1 complex formation in carcinoma dedifferentiation is
not clearly defined yet, LMO4 acts as a dominant negative by
interacting with LDB1, thereby competing for binding between
LDB1 and transcription factors. This dominant-negative effect of
LMO4 inhibits differentiation of neuronal cells (Thaler et al, 2002).
It is possible to speculate that increased expression of LMO4 may
inhibit differentiation and accelerate invasion of oral carcinoma
cells.
Another intriguing possibility comes from a study that GATA
zinc-finger proteins interact with the LMO2–LDB1 complex and
specifies a haematopoietic lineage differentiation (Wadman et al,
1997). However, overexpression of LMO2 in T-cell leukaemia
results in the formation of a novel aberrant complex that
substitutes a GATA protein to the E-box (CANNTG) binding
bHLH and inhibits T-cell differentiation (Gru ¨tz et al, 1998). The
C. elegans homologue of GATA, Elt, is a prerequisite for
ectodermal cell differentiation (Gilleard and McGhee, 2001).
GATA3 is expressed in the normal cervical squamous epithelial
cells, but downregulated in progressive carcinoma cells (Steenber-
gen et al, 2002), suggesting a role of GATA in epithelial cell
differentiation. The cis-acting E-box element is found in the E-
cadherin promoter region and binding of the zinc-finger protein,
SNAIL or SIP1, represses gene expression. E-cadherin
has a central role in maintenance of the epithelial cell-type
characteristic and the SNAIL/SIP1 inhibition of E-cadherin
expression in squamous carcinoma cells accelerates dedifferentia-
tion and invasion (Battle et al, 2000; Cano et al, 2000; Carver et al,
2001; Comijn et al, 2001). Our preliminary study showed
significant expression of the SNAIL and SIP1 genes in oral
carcinomas (T Chiba and K Imai, manuscript in preparation).
Although GATA expression in oral carcinomas is not yet known, it
could be intriguing if misexpression of LMO4 results in substitu-
tion of GATA to SNAIL/SIP1 and inhibits carcinoma cell
differentiation.
It is interesting to note that the carcinoma cells that
metastasised to the cervical lymph nodes exhibited increased
immunoreactivity to both LMO4 and LDB1 when compared to the
corresponding primary sites of tumour. An increased reaction in
the metastasised carcinoma cells suggests that LMO4- and LDB1-
expressing carcinoma cells at the primary sites may ease the
progress toward metastasis. It might also be plausible that the
metastasised carcinoma cells upregulate LMO4 and LDB1 in the
milieu of the lymph node. It is known that the local microenvir-
onment modifies carcinoma cell differentiation (Aboseif et al,
1999; Liotta and Kohn, 2001). Further studies should be addressed
to demonstrate a direct role for LMO4 and LDB1 in carcinoma
metastasis.
The present study demonstrated that LMO4 and LDB1 form a
protein complex and are overexpressed at the carcinoma
invasive front, and in less-differentiated and metastasised
squamous carcinoma cells. It suggests that misexpression of
LMO4 and LDB1 expression may play a role in progression
of neoplasm. Future avenues of research will clarify transcrip-
tional partners and target genes of LMO4–LDB1 complexes, and
elucidate the role of this pathway in the pathology of squamous cell
carcinomas.
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Figure 5 Immunoreactivity of LMO4 and LDB1 at the primary site of
carcinomas (A) and in metastasised lymph nodes (B). (A) A positive direct
correlation between LMO4 (horizontal line) and LDB1 (vertical line)
immunoreactivity was found by simple linear regression (r
2¼0.669,
Po0.01, n¼49). Open circles, crossed, and shaded circles indicated well,
moderately, and poorly differentiated squamous cell carcinomas, respec-
tively. (B) The percentage of immunoreactive carcinoma cells in primary
sites and metastasised cervical lymph nodes (LMO4; left, LDB1; right) was
analysed by Wilcoxon’s signed-rank test (Po0.05).
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